Business
Humacyte, Inc. Announces Pricing of $20 Million Registered Direct Offering of Common Stock
Net proceeds from the offering will fund the commercialization of Symvess® in the vascular trauma indication and provide funding beyond key milestones such as
About this update from Humacyte, Inc.
[{"type":"text","content":"Net proceeds from the offering will fund the commercialization of Symvess® in the vascular trauma indication and provide funding beyond key milestones such as the upcoming read-out of Phase 3 results in hemodialysis The offering was led by a new life science dedicated investor and a long-only mutual fund DURHAM, N.C., March 19, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has entered into a securities purchase agreement with several new institutional investors for the purchase and sale of 25,000,000 shares of common stock pursuant to a registered direct offering. The offering was led by a new life science dedicated investor and a long-only mutual fund. The gross proceeds from this offering are expected to be $20 million, before deducting offering expenses. The offering is expected to close on or about March 20, 2026, subject to satisfaction of customary closing conditions. All of the shares of common stock are being sold by Humacyte. Titan Partners, a division of American Capital Partners, is acting as sole placement agent for the offering. Humacyte intends to use the net proceeds that it will receive from the offering to fund the commercialization of Symvess in the vascular trauma indication, the planned filing of a Biologics License Application supplement in a hemodialysis indication and related activities including the upcoming read-out of Phase 3 results, the development of the product candidates in Humacyte’s pipeline and for working capital and general corporate purposes. A shelf registration statement on Form S-3 (No. 333-290231) was previously filed with the Securities and Exchange Commission (the “SEC”) on September 12, 2025 and declared effective by the SEC on September 22, 2025. The securities are being offered by means of a prospectus supplement and accompanying prospectus relating to the offering that form a part of the registration statement. The prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Before investing in the offering, you should read each of the prospectus supplement and the accompanying prospectus relating to the offering in th...